ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Having Applied for IPO to HKEX, What to Expect on Advaccine R&D Pipelines beyond COVID-19 DNA Vaccine
August 06, 2021An army of enterprises sought for IPO at Hong Kong, S.A.R., China in the almost first half of 2021. Not long ago, a prospectus submitted by Beijing Advaccine Biotechnology (hereinafter, "Advaccine") for listing caused a sensation, and the launch of its co -
Crushing Defeats—Top Ten R&D Pipelines that Failed in the Second Half of 2017
February 11, 2018Although the Phase I through Phase III failure rate is 90-95%, the odds of success may still be improved in the next generation of drugs launched.
Pharma Sources Insight January 2025
